Microbiological Testing of Vegan and Natural Cosmetic Products
Innovation on cosmetics and the higher demand for natural and vegan products may represent a risk, particularly when it comes to cosmetics microbiological contamination or the induction of sensitization. he microbiological testing and control constitutes a major part of quality control of a cosmetic product. It is essential to ensure the product's safety during normal and foreseeable conditions of use and its shelf life.

MICROBIOLOGICAL TESTING LEGAL REQUIREMENTS

According to the European Cosmetic Regulation no. 1223/2009, data on microbiological quality must be indicated in the Cosmetic Product Safety Report (CPSR), which is included in the Product Information File (PIF). Moreover, “particular attention shall be paid to cosmetics used around the eyes, on mucous membranes in general, on damaged skin, on children under three years of age, on elderly people and persons showing compromised immune responses”. It is mandatory to present in the CPSR the results of a preservation challenge test.

The total count of aerobic mesophilic microorganisms (bacteria, yeasts and moulds) and the absence specific microorganisms (Candida albicans, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli) should be included. For products intended to be used around the eyes, in the mucous membranes or products intended to be used in children under three years of age, the limit for the total count of aerobic mesophilic microorganisms is 100 CFU/ml or g (for other products is 1000 CFU/ml or g)

There are several accepted methods for performing preservative efficacy testing, commonly called Challenge test, of cosmetic products. ISO 11930:2012 and the European Pharmacopeia Preservative Efficacy Test Method 5.1.3 are examples of such methods. ISO 11930:2012 was revised by ISO 11930:2019 and it specifies a procedure for interpretation of data generated by the preservation efficacy test, the microbiological risk assessment, or both, when evaluating the overall antimicrobial protection of a cosmetic product. This ISO comprises a preservation efficacy test and a procedure for evaluating antimicrobial protection of a cosmetic product that is not considered low risk based on the assessment described in ISO 29621. According to this last ISO, some products are considered low risk and do not need to go through a challenge test (e.g. products with pH below 3 or above 10).

VEGAN AND NATURAL PRODUCTS

Guidelines for technical definitions and criteria regarding natural and organic cosmetics were issued by ISO (ISO 16128) as discussed in one of our previous posts.

Currently in the EU, there is not a clearly regulatory definition of a ‘vegan’ cosmetic product. However, regardless of the type of cosmetic product (vegan, organic, natural) we are talking about, it still has to comply with the European Cosmetic Regulation (EU) No 1223/2009 and the Commission Regulation (EU) No 655/2013 concerning the justification of claims on cosmetics. Companies that are claiming to be ‘vegan’ or to place on the market ‘vegan’ products rely on their duly justified standalone claim substantiation or certification from a third party with technical recognition for that purpose.

The trendy vegan and natural products use higher risk materials and have less preservatives to choose from. Therefore, they can represent a higher risk of microbiological contamination and preventing such contamination becomes an important problem to product manufacturers.

Microbiological testing of cosmetics, which is mandatory to perform, involves neutralizers (used to deactivate a preservative and allow the growth of microorganisms) and culture media (where microorganisms grow and are quantified) that are usually animal-derived. This constitutes a problem and is a point of discussion when we are talking about natural and vegan products. There are companies that are already replacing the culture media and neutralizers most commonly used by synthetic and plant-derived alternatives.

For the manufacturing of all products it is essential to maintain Good Manufacturing Practices (GMP). This could be quite challenging, but internal and external audits and validations are the best tools to achieve it. If you need further information or advice on how to do this, we can help you. Feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. ISO 11930:2019. Cosmetics – Microbiology – Evaluation of the antimicrobial protection of a cosmetic product.
  3. ISO 29621:2017. Cosmetics – Microbiology – Guidelines for the risk assessment and identification of microbiologically low-risk products.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »